Cat. No. 3412
Alternative Name: 4-OH-TAM
Chemical Name: 4-[(1Z)-1-[4-[2-(Dimethylamino)etho
Biological ActivityEstrogen receptor antagonist. Tamoxifen (Cat. No. 0999) metabolite; exhibits greater potency than the parent compound. Chemotherapeutic agent. Also activates intein-linked inactive Cas9, reducing off-target CRISPR-mediated gene editing.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Davis et al (2015) Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat.Chem.Biol. 11 316. PMID: 25848930.
Desta et al (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J.Pharm.Exp.Ther. 310 1062. PMID: 15159443.
Yu and Forman (2003) Simple and efficient production of (Z)-4-hydroxytamoxifen, a potent estrogen receptor modulator. J.Org.Chem. 68 9489. PMID: 14629178.
Jordan et al (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J.Endocrinology 75 305. PMID: 591813.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses (Z)-4-Hydroxytamoxifen from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (Z)-4-Hydroxytamoxifen, supplier, estrogen, receptors, antagonists, ER, 4-hydroxy-TAM, antiestrogens, antioestrogens, SERM, selective, modulators, CRISPR, Cas9-intein, Tocris Bioscience, Estrogen and Related Receptor Modulator products
Find multiple products by catalog number
New Products in this Area
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonistIP7e
Potent Nurr1 activatorBexarotene
Potent and selective RXR agonistGSK 2033
Potent LXR antagonist
September 20 - 22, 2016